Incb28060
WebJan 4, 2024 · Capmatinib (INCB28060) is a potent and selective c-MET kinase inhibitor. Capmatinib (INCB28060) inhibits c-MET kinase activity with an average IC50 of 0.13 nM. Properties Spectrum Names Capmatinib (INCB28060) Biological Activity Chemical & Physical Properties Synthetic Route Total: 1 Page Precursor & DownStream Synonyms WebINCB28060, also known as Capmatinib and INC280, is a novel and ATP-competitive inhibitor of c-Met with IC50 of 0.13 nM. c-Met, also named as hepatocyte growth factor receptor (HGFR) is a receptor tyrosine kinase that is essential for …
Incb28060
Did you know?
WebMay 27, 2024 · Capmatinib (INCB28060) is a highly potent and selective MET inhibitor that blocks c-MET phosphorylation in lung cancer cell lines at half-maximal inhibitory concentration values of 0.3 to 0.7 nmol/L. 14 In the phase II GEOMETRY mono-1 trial, patients with MET exon 14 skipping alterations and various levels of copy-number gain … WebReceptor Insulinolikog faktora rasta 1 (IGF-1) jest protein ćelijske površine koji je kod ljudi kodiran genom IGF-1 sa hromosoma 15.To je transmembranski receptor koji se aktivira hormonom koji se zove insulinoliki faktor rasta 1 i srodnim hormonom zvanim IGF-2.Pripada velikoj klasi tirozin-kinaznih receptora. Ovaj receptor posreduje u efektima IGF-1, koji je …
WebAlternate Names: 2-fluoro-N-methyl-4- (7- (quinolin-6-ylmethyl)imidazo [1,2-b] [1,2,4]triazin-2- yl)benzamide Application: INCB28060 is a novel inhibitor of Met (IC50 = 0.13 nM) CAS Number: 1029712-80-8 Purity: ≥99% Molecular Weight: 412.42 Molecular Formula: C 23 H 17 FN 6 O For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WebOct 20, 2010 · Incyte and Novartis signed a collaboration and license agreement for INCB18424 and Incyte’s Phase I-stage cMET inhibitor candidate INCB28060 in November 2009. http://www.rx-8.com/customized/219039.html
WebResults: INCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases. This inhibitor …
WebEnasidenib (INN; trade name Idhifa) is a medication used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test. It is an inhibitor of IDH2. It was developed by Agios Pharmaceuticals and is licensed to Celgene … sly cooper fanfiction kidsWebSynonyms: INC-280 2HCl, INCB28060 2HCl, INCB28060盐酸盐. INCB-28060 (free base) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.INCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10, 000-fold selectivity over a large panel of human kinases. sly cooper fanfiction cribWebDescription: Capmatinib (formerly also known as INCB-28060; INC280; Tabrecta) is a novel, potent, orally bioavailable, ATP-competitive inhibitor of c-MET with potential antitumor … sly cooper franchiseWebCapmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and … solar power panels factoryWebINCB28060, a novel inhibitor of c-MET kinase. INCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a … solar power panels informationWebBuy INCB28060 (CAS 1029712-80-8), a novel inhibitor of Met (IC50 = 0.13 nM), from Santa Cruz. Purity: ≥99%, Molecular Formula: C23H17FN6O, MW: 412.42 Choose a Store solar power pentictonhttp://bbs.jiatuxueyuan.com/home.php?mod=space&uid=600275 solar power panels in tamilnadu